Literature DB >> 15728475

Platelet factor 4 differentially modulates CD4+CD25+ (regulatory) versus CD4+CD25- (nonregulatory) T cells.

Chao Yan Liu1, Manuela Battaglia, Seon Ho Lee, Qi-Hong Sun, Richard H Aster, Gian Paolo Visentin.   

Abstract

Active suppression mediated by CD4(+)CD25(+) T regulatory (Tr) cells plays an important role in the down-regulation of T cell responses to both foreign and self-Ags. Platelet factor 4 (PF4), a platelet-derived CXC chemokine, has been shown to strongly inhibit T cell proliferation as well as IFN-gamma and IL-2 release by isolated T cells. In this report we show that human PF4 stimulates proliferation of the naturally anergic human CD4(+)CD25(+) Tr cells while inhibiting proliferation of CD4(+)CD25(-) T cells. In coculture experiments we found that CD4(+)CD25(+) Tr cells exposed to PF4 lose the ability to inhibit the proliferative response of CD4(+)CD25(-) T cells. Our findings suggest that human PF4, by inducing Tr cell proliferation while impairing Tr cell function, may play a previously unrecognized role in the regulation of human immune responses. Because platelets are the sole source of PF4 in the circulation, these findings may be relevant to the pathogenesis of certain immune-mediated disorders associated with platelet activation, such as heparin-induced thrombocytopenia and autoimmune thrombocytopenic purpura.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15728475     DOI: 10.4049/jimmunol.174.5.2680

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  34 in total

1.  CXCL4 mediates tumor regrowth after chemotherapy by suppression of antitumor immunity.

Authors:  Yang Zhang; Jing Gao; Xia Wang; Shaorong Deng; Hao Ye; Wen Guan; Mingyuan Wu; Shunying Zhu; Yan Yu; Wei Han
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

2.  Platelet factor 4 limits Th17 differentiation and cardiac allograft rejection.

Authors:  Guanfang Shi; David J Field; Kyung-ae Ko; Sara Ture; Kalyan Srivastava; Scott Levy; M Anna Kowalska; Mortimer Poncz; Deborah J Fowell; Craig N Morrell
Journal:  J Clin Invest       Date:  2014-01-27       Impact factor: 14.808

Review 3.  Platelets: at the nexus of antimicrobial defence.

Authors:  Michael R Yeaman
Journal:  Nat Rev Microbiol       Date:  2014-06       Impact factor: 60.633

4.  Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis.

Authors:  Lenny van Bon; Alsya J Affandi; Jasper Broen; Romy B Christmann; Renoud J Marijnissen; Lukasz Stawski; Giuseppina A Farina; Giuseppina Stifano; Allison L Mathes; Marta Cossu; Michael York; Cindy Collins; Mark Wenink; Richard Huijbens; Roger Hesselstrand; Tore Saxne; Mike DiMarzio; Dirk Wuttge; Sandeep K Agarwal; John D Reveille; Shervin Assassi; Maureen Mayes; Yanhui Deng; Joost P H Drenth; Jacqueline de Graaf; Martin den Heijer; Cees G M Kallenberg; Marc Bijl; Arnoud Loof; Wim B van den Berg; Leo A B Joosten; Vanessa Smith; Filip de Keyser; Rafaella Scorza; Claudio Lunardi; Piet L C M van Riel; Madelon Vonk; Waander van Heerde; Stephan Meller; Bernhard Homey; Lorenzo Beretta; Mark Roest; Maria Trojanowska; Robert Lafyatis; Timothy R D J Radstake
Journal:  N Engl J Med       Date:  2013-12-18       Impact factor: 91.245

5.  Generation and Characterization of a New Monoclonal Antibody Against CXCL4.

Authors:  Jing Gao; Mingyuan Wu; Jin Gao; Xia Wang; Yang Zhang; Shunying Zhu; Yan Yu; Wei Han
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2015-04

6.  Circulating leukocyte-platelet complexes as a predictive biomarker for the development of immune-related adverse events in advanced non-small cell lung cancer patients receiving anti-PD-(L)1 blocking agents.

Authors:  Carlos Zamora; Mariona Riudavets; Margarita Majem; Silvia Vidal; Georgia Anguera; Letícia Alserawan; Ivana Sullivan; Andrés Barba; Jorgina Serra; M Angels Ortiz; Pablo Gallardo; Lidia Perea; Javier Gavira; Agustí Barnadas
Journal:  Cancer Immunol Immunother       Date:  2021-01-02       Impact factor: 6.968

Review 7.  Type I interferon in rheumatic diseases.

Authors:  Theresa L Wampler Muskardin; Timothy B Niewold
Journal:  Nat Rev Rheumatol       Date:  2018-03-21       Impact factor: 20.543

Review 8.  Immune pathogenesis of heparin-induced thrombocytopenia.

Authors:  Sanjay Khandelwal; Gowthami M Arepally
Journal:  Thromb Haemost       Date:  2016-07-28       Impact factor: 5.249

9.  Regulatory T Cells Control PF4/Heparin Antibody Production in Mice.

Authors:  Yongwei Zheng; Wen Zhu; Dipica Haribhai; Calvin B Williams; Richard H Aster; Renren Wen; Demin Wang
Journal:  J Immunol       Date:  2019-08-30       Impact factor: 5.422

10.  Immune complexes formed following the binding of anti-platelet factor 4 (CXCL4) antibodies to CXCL4 stimulate human neutrophil activation and cell adhesion.

Authors:  Zhihua Xiao; Gian P Visentin; Kannayakanahalli M Dayananda; Sriram Neelamegham
Journal:  Blood       Date:  2008-06-06       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.